Quality of life in a clinical trial of highly active antiretroviral therapy alone or with intravenous or subcutaneous interleukin-2 administration
Article Abstract:
Health-related quality of life (HRQOL) outcomes in a randomized clinical trial sponsored by the adult aids Clinical Trials Group (aaCTG) of the National Institutes of Health, aaCTG Protocol 328 that was assessed is described. Evidence of a short-term but not long-term adverse impact of interleukin-2 on HRQOL and some evidence on long term benefit for the subcutaneous group are found.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Gene therapy of HIV infection by transduced autologous CD4 T-cells inhibiting viral entry
Article Abstract:
Data on the preclinical development strategy for a novel gene therapy approach mediated by transduced autologus CD4 T-cells were presented. A positive relation between the absolute number of transfected CD4 T-cells and increases of CD4 counts was observed.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Daily low-dose subcutaneous interleukin-2 added to single- or dual- nucleoside therapy in HIV infection does not protect against CD4 (super +) T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial
- Abstracts: Antihypertensive treatment based on conventional or ambulatory blood pressure measurement: a randomized controlled trial